Skip to main content

Site notifications

MOUNJARO Eli Lilly Australia Pty Ltd

Product name
MOUNJARO
Accepted date
Sep-2024
Active ingredients
tirzepatide
Proposed indication
Treatment of moderate to severe obstructive sleep
apnoea (repeated stopping and starting of breathing during sleep) in adults with obesity.
Application type
C (new indication)
Publication date
Sep-2024

Help us improve the Therapeutic Goods Administration site